BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $138 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $108 at BMO Capital
August 5, 2020 9:46 AM EDTBMO Capital analyst George Farmer raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $108.00 (from $94.00) while maintaining a Market Perform rating.
The analyst commented, "Following model adjustments, we increase our PT to $108 from $94 and maintain our Market Perform rating ahead... More
